Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects

Scandinavian Journal of Primary Health Care

Volumn 29, Issue 2, 2011, Pages 85-91

  Heldgaard, Poul Erik ^a,b   Henriksen, Jan Erik ^c   Sidelmann, Johannes J ^d   Olivarius, Niels De Fine ^b   Siersma, Volkert D ^b   Gram, Jørgen B ^d  

^a Ørum Health Centre   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cross sectional survey; general practice; population based; screen detected; type 2 diabetes

Indexed keywords

LIPID;

ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; QUESTIONNAIRE; RISK FACTOR;

ADULT; AGED; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPIDS; MALE; MASS SCREENING; MIDDLE AGED; OVERWEIGHT; QUESTIONNAIRES; RISK FACTORS;

EID: 79956199005     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.3109/02813432.2011.565164     Document Type: Article

References (34)

1. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1-11.
2. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9. (Pubitemid 32893993)
3. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: A review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003;138:215-29. (Pubitemid 36231628)
4. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish popu¬lation: The Inter99 study. Diabetes Care 2003;26:2335-40. (Pubitemid 36993322)
5. Diabetes UK. Position statement: Early identification of people with Type 2 diabetes. http://www.diabetes.org.uk/infocentre/state/downloads/earlyid.doc, accessed November 3 2009.
6. American Diabetes Association. Screening for type 2 diabe¬tes: Position statement. Diabetes Care 2004;27(Suppl 1): S11-4.
7. Wareham NJ, Griffin SJ. Should we screen for type 2 diabe¬tes? Evaluation against National Screening Committee crite¬ria. BMJ 2001;322:986-8. (Pubitemid 32374692)
8. Feig DS, Palda VA, Lipscombe L. Screening for type 2 dia¬betes mellitus to prevent vascular complications: Updated recommendations from the Canadian Task Force on Preven¬tive Health Care. CMAJ 2005;172:177-80.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular compli¬cations in type 2 diabetes (UKPDS 38). BMJ 1998;317: 703-13.
10. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) ran¬domised trial. HOT Study Group. Lancet 1998;351:1755-62. (Pubitemid 28269185)
11. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20. (Pubitemid 27143424)
12. Alberti KGMM, Zimmet PZ. Definition, diagnosis and clas-sification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med 1998;15: 539-53. (Pubitemid 28319935)
13. Heldgaard PE, Olivarius NF, Hindsberger C, Henriksen JE. Impaired fasting glycaemia resembles impaired glucose toler¬ance with regard to cardiovascular risk factors: Population-based, cross-sectional study of risk factors for cardiovascular disease. Diabet Med 2004;21:363-70. (Pubitemid 38519673)
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc Series B 1995;57:289-300.
16. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Dia¬betes Care 1992;15:815-19.
17. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk: The ADDITION study. Diabetologia 2008;51:1127-34.
18. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: The Hoorn Screening Study. Diabetes Care 2003;26:2604-8. (Pubitemid 37052107)
19. Spijkerman AM, Henry RM, Dekker JM, Nijpels G, Kostense PJ, Kors JA, et al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screen¬ing and patients newly diagnosed in general practice: The Hoorn Screening Study. J Intern Med 2004;256:429-36. (Pubitemid 39434380)
20. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24. (Pubitemid 28172927)
21. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
22. Kuk JL, Ardern CI. Are metabolically normal but obese indi¬viduals at lower risk for all-cause mortality? Diabetes Care 2009;32:2297-9.
23. Olivarius N de F, Andreasen AH, Siersma V, Richelsen B, Beck-Nielsen H. Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. Diabetologia 2006;49:2058-67. (Pubitemid 44168472)
24. Olivarius N de F, Richelsen B, Siersma V, Andreasen AH, Beck-Nielsen H. Weight history of patients with newly diag¬nosed Type 2 diabetes. Diabet Med 2008;25:933-41.
25. Guidelines for using serum cholesterol, high-density lipopro-tein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians, Part 1. Ann Intern Med 1996;124:515-17.
26. LaRosa JC, Pearson TA. Cholesterol screening guidelines consensus, evidence, and the departure from common sense. Circulation 1997;95:1651-3. (Pubitemid 27142827)
27. Danielsson B, Vancheri F, Aberg H, Strender LE. Hyperlipi-daemia: Differences in management practices and attitudes in two regions in Europe-Sicily and the Stockholm area. Eur J Epidemiol 1998;14:477-82. (Pubitemid 28370784)
28. Cederholm J, Eliasson B, Nilsson PM, Weiss L, Gudbjorns-dottir S. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract 2005;67: 258-66. (Pubitemid 40254316)
29. Nagi DK, Mohamed A, V, Jain SK, Walji S, Yudkin JS. Plas-minogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tol¬erance (IGT) or non-diabetic Asians. Diabet Med 1996;13:59-64. (Pubitemid 26046597)
30. Yach D, Alberti G. Screening for Type 2 diabetes. Report of a World Health Organization and International Diabetes Federation Meeting. Report No. WHO/NMH/MNC/03.1. Geneva: World Health Organization; 2003.
31. Heldgaard PE, Griffin SJ. Routinely collected general practice data aids identification of people with hypergly-caemia and metabolic syndrome. Diabet Med 2006;23: 996-1002. (Pubitemid 44257944)
32. Wilson JMG JG. Principles and practice of screening for dis¬ease. World Health Organisation; 1968. Report No. 34. http://whqlibdoc.who.int/php/ WHO-PHP-34.pdf (accessed February 14, 2011).
33. Spigt M, Rikkers A, Doornbos M, Wouters E, Spitz I, Van AL, et al. The effect of screening on the prevalence of diag¬nosed type 2 diabetes in primary care. Scand J Prim Health Care 2009;27:232-7.
34. Juul L, Sandbaek A, Foldspang A, Frydenberg M, Borch-Johnsen K, Lauritzen T. Adherence to guidelines in people with screen-detected type 2 diabetes, ADDITION, Denmark. Scand J Prim Health Care 2009;27:223-31.